Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 2-hydroxy-4-[[2-[[(4-methylphenyl)sulfonyl]oxy]acetyl]amino]-benzoic acid
- Correlated keywords
- STAT3 inhibitors inhibits inhibitions VI STAT transcriptions factors TFs vasculars diseases hypertension cardiac hearts hypertrophy S3I201 S3I 201 STATs STAT-3 3 activations active activators dimerizations genes IL-6 ILs 6 IL6 interleukins T-cells T cells angiotensin II oxidative stress endothelial dysfunctions collagen in vitro NSCs 74859 NSC-74859 NSC74859 signals transducers cytoplasms cytoplasmic cells membranes nucleus humans tumors upstream tyrosines kinases types 1 AT1 ATs receptors inflammatory mediators suppresses suppressions phosphorylations biosynthesis atrial natriuretic b-myosins beta-myosin .beta.-myosin ?-myosin heavy chains models
- Product Overview:
Signal transducers and activators of transcription (STATs) are a family of latent cytoplasmic transcription factors that convey signals from the cell membrane to the nucleus. In various human tumors, STAT3 is constitutively activated by aberrant upstream tyrosine kinase activities.{23053} STAT signaling is also suspected to play a role in vascular disease since it can be activated through angiotensin II type 1 receptors or the inflammatory mediator interleukin (IL)-6.{23262} S3I-201 is an inhibitor of STAT3 transcription factor activation, dimerization, and gene transcription. It can suppress IL-6-induced phosphorylation of STAT3 in T cells with an IC50 value of 38 ?M.{23263} Inhibiting STAT3 activation with 10 ?M S3I-201 was demonstrated to be protective against angiotensin II-induced oxidative stress, endothelial dysfunction, and hypertension in two different models of vascular disease.{23262} At 10 ?M, S3I-201 has also been used as a means to regress cardiac hypertrophy by inhibiting collagen biosynthesis and decreasing atrial natriuretic factor and ?-myosin heavy chain in an in vitro model.{23264}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.